Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

393 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 4 of 9

  1. HEART to HAART

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  2. Heart Rate Variability Biofeedback

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Smoking

    phase 2 mab completed

    1 trial

  3. Heroin Dependence

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule terminated

    1 trial

  4. High-dose donepezil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorders

    phase 2 small molecule completed

    1 trial

  5. Hydroxycarbamid

    BRIGHT MINDS BIOSCIENCES INC.

    Central Retinal Vein Occlusion, Non-Ischemic

    phase 2 small molecule active

    1 trial

  6. IVPT

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  7. Ibudilast

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  8. Immune Globulin Intravenous (IVIG)

    BRIGHT MINDS BIOSCIENCES INC.

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  9. Immunization with P. vivax irradiated sporozoites

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria

    phase 2 mab completed

    1 trial

  10. Inactive Marijuana (0% THC)

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Smoking

    phase 2 small molecule completed

    1 trial

  11. Interactive injection and sexual risk intervention

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  12. Intermittent Oral Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine

    phase 2 small molecule completed

    1 trial

  13. Intervention Condition

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  14. Isradipine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  15. KLWS-V502-02

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial

  16. Ketamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  17. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  18. L-Glutamine

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Hypertension

    phase 2 small molecule completed

    1 trial

  19. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  20. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 2 other completed

    1 trial

  21. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  22. LX1001

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 mab completed

    1 trial

  23. Labetalol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  24. Lamotrigine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  25. Lemborexant

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interaction

    phase 2 small molecule completed

    1 trial

  26. Lidocaine HCl

    BRIGHT MINDS BIOSCIENCES INC.

    Postherpetic Neuralgia

    phase 2 small molecule active

    1 trial

  27. Linezolid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Meningeal

    phase 2 small molecule completed

    1 trial

  28. Linezolid

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  29. Liraglutide Pen Injector

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Substitution Treatment

    phase 2 small molecule completed

    1 trial

  30. Lisdexamfetamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  31. Lithium Carbonate

    BRIGHT MINDS BIOSCIENCES INC.

    Frontotemporal Dementia (FTD)

    phase 2 small molecule completed

    1 trial

  32. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule completed

    1 trial

  33. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  34. Lorazepam

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule terminated

    1 trial

  35. Lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  36. Lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 2 small molecule completed

    1 trial

  37. Low Dose Modafinil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  38. M-CPP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    2 trials

  39. MI-CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Abuse

    phase 2 other completed

    1 trial

  40. MI/CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholic, Marijuana Misuse

    phase 2 other completed

    1 trial

  41. MN-166 (50 mg) First

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Abuse

    phase 2 small molecule completed

    1 trial

  42. Marijuana blunt

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule completed

    1 trial

  43. Matching placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Familial Dysautonomia

    phase 2 small molecule active

    1 trial

  44. Mazindol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  45. Memantine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  46. Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)

    BRIGHT MINDS BIOSCIENCES INC.

    Meningitis

    phase 2 mab active

    1 trial

  47. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  48. Methamphetamine

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Intoxication

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.